title: Harnessing the innate immune system to treat cancer: enhancement of antibody-dependent cellular cytotoxicity with anti-CD137 Ab.
authors.affiliation: Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA; Department of Clinical Pharmacology & Therapeutics, Kyoto University Hospital, Sakyo-ku, Kyoto, Japan.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Yonezawa
authors.affiliation: Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA; Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA, USA.
authors.forename: Cariad
authors.initials: C
authors.lastname: Chester
authors.affiliation: Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA.
authors.forename: Narendiran
authors.initials: N
authors.lastname: Rajasekaran
authors.affiliation: Division of Oncology, Department of Medicine, Stanford University, CCSR Building, Room 1110, Stanford, CA 94305, USA. kohrt@stanford.edu.
authors.forename: Holbrook E
authors.initials: HE
authors.lastname: Kohrt
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000920:Antibody-Dependent Cell Cytotoxicity / Q000187:drug effects / Q000276:immunology*; D002986:Clinical Trials as Topic; D006801:Humans; D007107:Immune System / Q000187:drug effects / Q000276:immunology*; D007167:Immunotherapy; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D011379:Prognosis; D053261:Tumor Necrosis Factor Receptor Superfamily, Member 9 / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D053261:Tumor Necrosis Factor Receptor Superfamily, Member 9
keywords: CD137 is a costimulatory receptor that belongs to the tumor necrosis factor receptor (TNFR) superfamily. CD137 is expressed on T cell, activated NK cells and other immune cells. We recently showed that an agonistic anti-CD137 mAb activates NK cells, resul; Efficacy of anti-CD137 mAb was examined by in vitro and in vivo experiments. Clinical trials of anti-CD137 mAb are also on-going.; Monoclonal antibodies are an invaluable therapeutic class when it comes to cancer therapy. One of the primary mechanisms of anti-tumor activity of monoclonal antibodies is antibody dependent cell-mediated cytotoxicity (ADCC) mediated by natural killer (NK; We discuss some of the promising strategies that could potentially enhance ADCC with anti-CD137 mAbs.